<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1501233102
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REBIF 44 MCG/0.5 ml Solution for injection in cartridge
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INTERFERON BETA-1A
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        132
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3958.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SERONO SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SERONO SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SERONO EUROPE LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AB07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rebif belongs to a class of medicines known as interferons. These are natural substances that transmit messages between cells. Interferons are produced by the body and play an essential role in the immune system. Through mechanisms that are not totally understood, interferons help to limit the damage of the central nervous system associated with multiple sclerosis.<br />Rebif is a highly purified soluble protein that is similar to the natural interferon beta that is produced in the human body.<br />Rebif is used for the treatment of multiple sclerosis. It has been shown to reduce the number and the severity of relapses and to slow the progression of disability. It is also approved for use in patients who have experienced a single clinical event likely to be a first sign of multiple sclerosis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Rebif<br />&bull; if you are allergic to natural or recombinant interferon beta or any of the other ingredients of this medicine (listed in section 6).<br />&bull; if you are severely depressed at present.<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before using Rebif.<br />&bull; Rebif should only be used under the supervision of your doctor.<br />&bull; Before treatment with Rebif, read carefully and follow the advice given under &ldquo;How to use Rebif&rdquo; in order to minimise the risk of injection site necrosis (skin breakdown and tissue destruction) that has been reported in patients treated with Rebif. If you experience troubling local reactions, contact your doctor.<br />&bull; Talk to your doctor or pharmacist before taking Rebif if you have an allergy (hypersensitivity) to any other medicines.</p><p>&bull; Blood clots in the small blood vessels may occur during your treatment. These blood clots could affect your kidneys. This might happen several weeks to several years after starting Rebif. Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidney.<br />Inform your doctor if you have a disease of<br />&bull; the bone marrow,<br />&bull; kidney,<br />&bull; liver,<br />&bull; heart,<br />&bull; thyroid,<br />&bull; or if you have experienced depression,<br />&bull; or if you have any history of epileptic seizures,<br />so that he/she can closely monitor your treatment and any worsening of these conditions.<br />Other medicines and Rebif<br />Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.<br />In particular you should tell your doctor if you are using antiepileptics or antidepressants.<br />Pregnancy and breast-feeding<br />If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />No harmful effects on the breastfed new born/infant are anticipated. Rebif can be used during breast-feeding.<br />Driving and using machines<br />Effects of the disease itself or of its treatment might influence your ability to drive or to use machines. You should discuss this with your doctor if you are concerned.<br />Rebif contains benzyl alcohol<br />Rebif contains 2.5 mg benzyl alcohol per dose. It must not be given to premature babies or neonates. It may cause toxic reactions and allergic reactions in infants and children up to 3 years old.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is for multidose use.<br />Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />Dose<br />Patients who have experienced a single clinical event<br />The usual dose is 44 micrograms (12 million IU) given three times per week.<br />Patients with multiple sclerosis<br />The usual dose is 44 micrograms (12 million IU) given three times per week.<br />A lower dose of 22 micrograms (6 million IU) given three times per week is recommended for patients who cannot tolerate the higher dose.<br />Rebif should be administered three times per week, and if possible:<br />&bull; on the same three days every week (at least 48 hours apart, e.g., Monday, Wednesday, Friday)<br />&bull; at the same time of day (preferably in the evening).</p><p>Use in children and teenagers (2 to 17 years old)<br />No formal clinical studies have been conducted in children or teenagers. However, there is some clinical data available suggesting that the safety profile in children and teenagers receiving Rebif 22 micrograms or Rebif 44 micrograms three times per week is similar to that seen in adults.<br />Use in children (below 2 years of age)<br />Rebif is not recommended for use in children below 2 years of age.<br />Method of administration<br />&bull; Rebif is intended for subcutaneous (under the skin) injection.<br />&bull; The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional. After receiving adequate training, you, a family member, friend or carer can use Rebif cartridges with your device to administer the medicine at home.<br />&bull; The cartridge is to be used either with the Rebismart electronic injection device, Discuss with your doctor which device is the most suitable for you.<br />&bull; Full instructions for use are provided with your device. Please follow these carefully.<br />&bull; Short instructions on how to use Rebif cartridges with each device are given below.<br />Before you start<br />&bull; Wash your hands thoroughly with soap and water.<br />&bull; Remove the Rebif cartridge from the blister pack by peeling back the plastic covering.<br />&bull; Check (just after removing from the refrigerator) that the cartridge is not accidentally frozen in the pack or inside the device. Only clear to opalescent solution without particles and without visible signs of deterioration should be used.<br />&bull; To place the cartridge in the device and perform the injection follow the instruction manual (Instructions for Use) provided with your device.</p><p>Where to inject Rebif<br />&bull; Choose an injection site. Your doctor will advise you on the possible injection sites (good sites include the upper thighs and the lower abdomen). It is recommended that you keep track of and rotate your injection sites, so that one area is not injected too frequently in order to minimise the risk of injection site necrosis.<br />NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find.<br />&bull; Before the injection, use an alcohol wipe to clean the skin at the injection site. Let the skin dry. If a bit of alcohol is left on the skin, you may get a stinging sensation.<br />How to inject Rebif<br />&bull; Your doctor will tell you how to choose the correct dose of 44 micrograms. Please read also the instructions in the manual provided with your device.<br />&bull; Your doctor may have prescribed you Rebismart device. If you have been prescribed Rebismart please go to the section &ldquo;If you use Rebismart&rdquo;.</p><p>&nbsp;</p><p>If you use Rebismart<br />&bull; Please ensure that the dose displayed on the screen of the device corresponds to the prescribed dose of 44 micrograms before the injection.<br />&bull; Place Rebismart at a right angle (90&deg;) to the skin.<br />&bull; Press the injection button. During the injection, the button will flash with a green light.<br />&bull; Wait until the green light switches off. This tells you that the injection is completed.<br />&bull; Remove Rebismart from the injection site.</p><p>&nbsp;</p><p>After the injection of Rebif with either Rebismart:<br />&bull; Remove and discard the needle according to the instruction manual provided with your device.<br />&bull; Gently massage the injection site with a dry cotton ball or gauze.<br />&bull; Store your device containing a cartridge of Rebif as instructed in section 5 &ldquo;How to store Rebif&rdquo;.<br />If you have any further questions, please ask your doctor, nurse or pharmacist.<br />If you use more Rebif than you should<br />In case of overdose, contact your doctor immediately.<br />If you forget to use Rebif<br />If you miss a dose, continue to inject from the day of the next scheduled dose. Do not use a double dose to make up for a forgotten dose.<br />If you stop using Rebif<br />The effects of Rebif may not be noticed immediately. Therefore, you should not stop using Rebif but continue to use it regularly to achieve the desired result. If you are uncertain about the benefits, please consult your doctor.<br />You should not discontinue the treatment without first contacting your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Tell your doctor immediately and stop using Rebif if you experience any of the following serious side effects:<br />&bull; Serious allergic (hypersensitivity) reactions. If, immediately following Rebif administration you experience a sudden difficulty breathing, which may appear in association with swelling of face, lips, tongue or throat, nettle rash, itching all over the body, and a feeling of weakness or faintness, contact your doctor immediately or seek urgent medical attention. These reactions are rare (may affect up to 1 in 1,000 people).<br />&bull; Inform your doctor immediately if you experience any of the following possible symptoms of a liver problem: jaundice (yellowing of the skin or of the whites of the eyes), widespread itching, loss of appetite accompanied by nausea and vomiting and easy bruising of the skin. Severe liver problems can be associated with additional signs, e.g. difficulty concentrating, sleepiness and confusion.</p><p>&bull; Depression is common (may affect up to 1 in 10 people) in treated patients with multiple sclerosis. If you feel depressed or develop thoughts of suicide, report it immediately to your doctor.<br />Talk to your doctor if you experience any of the following side effects:<br />&bull; Flu-like symptoms, such as headache, fever, chills, muscle and joint pains, fatigue and nausea are very common (may affect more than 1 in 10 people).<br />These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use.<br />To help reduce these symptoms your doctor may advise you to take a fever reducing painkiller before a dose of Rebif and then for 24 hours after each injection.<br />&bull; Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common.<br />The occurrence of injection site reactions usually decreases over time.<br />Tissue destruction (necrosis), abscess and mass at injection site are uncommon (may affect up to 1 in 100 people).<br />See recommendations in section &ldquo;Warnings and precautions&rdquo; to minimise the risk of injection site reactions.<br />The injection site can become infected (uncommon); the skin may become swollen tender and hard and the whole area could be very painful. If you experience any of these symptoms, contact your doctor for advice.<br />&bull; Certain laboratory tests may change. These changes are generally not noticed by the patient (no symptoms), are usually reversible and mild, and most often do not require particular treatment.<br />The number of red blood cells, white blood cells or platelets may decrease either individually (very common) or all at one time (rare). Possible symptoms resulting from these changes could include tiredness, reduced ability to fight infection, bruising or unexplained bleeding.<br />Liver function tests may be disturbed (very common). Inflammation of the liver has also been reported (uncommon). If you experience symptoms suggesting a liver disorder, such as loss of appetite accompanied by other symptoms such as nausea, vomiting, jaundice, please contact your doctor immediately (see above &ldquo;Tell your doctor immediately...&rdquo;).<br />&bull; Thyroid dysfunction is uncommon. The thyroid gland may function either excessively, or insufficiently. These changes in the thyroid activity are almost always not felt by the patient as symptoms; however, your doctor may recommend testing as appropriate.<br />&bull; MS pseudo-relapse (frequency not known): There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse. For example, your muscles may feel very tense or very weak, preventing you from moving as you want. In some cases, such symptoms are associated with fever or flu-like symptoms described above. If you notice any of these side effects talk to your doctor.</p><p>Other possible side effects include:<br />Very common (may affect more than 1 in 10 people):<br />&bull; Headache<br />Common (may affect up to 1 in 10 people):<br />&bull; Insomnia (sleeping difficulty)<br />&bull; Diarrhoea, nausea, vomiting<br />&bull; Itching, rash (skin eruptions)<br />&bull; Muscle and joints pain<br />&bull; Fatigue, fever, chills</p><p>&bull; Hair loss<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Hives<br />&bull; Epileptic seizures<br />&bull; Liver inflammation (hepatitis)<br />&bull; Breathing difficulties<br />&bull; Blood clots such as deep venous thrombosis<br />&bull; Disorders of the retina (back of the eye) such as inflammation or blood clots with consequent vision disorders (vision disturbances, loss of vision)<br />&bull; Increased sweating<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; Suicide attempt<br />&bull; Serious skin reactions - some with mucosal lesions<br />&bull; Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. Your doctor may find changes in your blood and the function of your kidneys.<br />&bull; Drug-induced lupus erythematosus: a side-effect of long-term use of Rebif. Symptoms may include muscle pain, joint pain and swelling, and rash. You may also experience other signs such as fever, weight loss, and fatigue. Usually symptoms disappear within one or two weeks after treatment is stopped.<br />&bull; Kidney problems including scarring that may reduce your kidney function.<br />If you get some or all of these symptoms:<br />- foamy urine<br />- fatigue<br />- swelling, particularly in the ankles and eyelids, and weight gain.<br />Tell your doctor as they may be signs of a possible kidney problem.<br />The following side effects were reported for interferon beta (frequency not known)<br />&bull; Dizziness<br />&bull; Nervousness<br />&bull; Loss of appetite<br />&bull; Dilatation of the blood vessels and palpitation<br />&bull; Irregularities and/or changes in menstrual flow<br />&bull; Pulmonary arterial hypertension - a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with Rebif.<br />You should not stop or alter the medication without your doctor&rsquo;s advice.<br />Children and teenagers<br />Side effects in children and teenagers are similar to those observed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label after EXP.<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze. (To prevent accidental freezing, avoid placing near the freezer compartment).<br />After first injection use within 28 days.<br />The device (Rebismart) containing a pre-filled cartridge of Rebif must be stored in the device storage box in a refrigerator (2&deg;C &ndash; 8&deg;C). For the purpose of ambulatory use, you may remove Rebif from the refrigerator and store it not above 25&deg;C for one single period of up to 14 days. Rebif must then be returned to the refrigerator and used before the expiry date.<br />Store in the original package in order to protect from light.<br />Do not use this medicine if you notice any visible signs of deterioration such as if the solution is no longer clear or if it contains particles.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away of medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Rebif contains<br />&bull; The active substance is interferon beta-1a. Each cartridge contains 132 micrograms corresponding to 36 million International Units (IU) of interferon beta-1a.<br />&bull; The other ingredients are mannitol, poloxamer 188, L-methionine, benzyl alcohol, sodium acetate, acetic acid, sodium hydroxide and water for injections.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Rebif looks like and contents of the pack
Pre-filled cartridge (type 1 glass) with a plunger stopper (rubber) and a crimp cap (aluminium and halobutyl rubber), containing 1.5 mL solution for injection. Pack size of 4 or 12 cartridges. Not all pack sizes may be marketed.
The cartridge is to be used either with the Rebismart electronic injection.The devices are provided separately. In some markets only one of these devices may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />Merck Serono Europe Ltd<br />56 Marsh Wall<br />London E14 9TP<br />United Kingdom<br />Manufacturer<br />Merck Serono S.p.A.<br />Via delle Magnolie 15<br />I-70026 Modugno (Bari)<br />Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 17 October 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ینتمي عقار ریبیف إلى فئة من الأدویة تعُرف بالإنترفیرونات. وھي عبارة عن مواد طبیعیة تنقل الرسائل بین الخلایا. ینتج الجسم<br />الإنترفیرونات وتؤدي دورًا جوھریاً في جھاز المناعة. ومن خلال آلیات لیست مفھومة بشكل كامل، تساعد الإنترفیرونات على الحد<br />من تضرر الجھاز العصبي المركزي المصاحب للتصلب المتعدد.<br />ریبیف عبارة عن بروتین قابل للذوبان عالي النقاء یشبھ الإنترفیرون بیتا الطبیعي الذي یتم إنتاجھ في الجسم البشري.<br />یسُتخدم ریبیف لعلاج التصلب المتعدد. وقد أثبت قدرتھ على خفض عدد وشدة الانتكاسات وإبطاء تدھور الإعاقة. مصرح باستخدامھ<br />أیضًا للمرضى الذین عانوا من حدث سریري واحد من المرجح أنھ علامة أولى على التصلب المتعدد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; إذا كانت لدیك حساسیة تجاه الإنترفیرون بیتا الطبیعي أو المأشوب أو أي من المكونات الأخرى لھذا الدواء (المذكورة في<br />.( القسم 6<br />&bull; إذا كنت تعاني من اكتئاب شدید في الوقت الراھن.<br />التحذیرات والاحتیاطات<br />استشر الطبیب أو الصیدلي أو الممرضة قبل استعمال ریبیف.<br />&bull; ینبغي عدم استعمال ریبیف إلا تحت إشراف طبیبك.<br />&bull; قبل العلاج بعقار ریبیف، اقرأ النصائح المقدمة تحت &quot;كیفیة استعمال ریبیف&quot; واتبعھا بعنایة لتقلل من خطر تنخر موضع<br />الحقن (تھتك الجلد وتلف الأنسجة) الذي أبلغ عنھ مرضى عوُلجوا بعقار ریبیف. إذا عانیت من تفاعلات موضعیة متعبة،<br />فاتصل بطبیبك.<br />&bull; تحدث مع طبیبك أو الصیدلي قبل أخذ ریبیف، إذا كنت تعاني من حساسیة (فرط تحسس) تجاه أي أدویة أخرى</p><p>&bull; قد تحدث جلطات دمویة في الأوعیة الدمویة الصغیرة خلال علاجك. قد تؤثر ھذه الجلطات الدمویة على كلیتیك. قد یحدث<br />ھذا بعد بدء استعمال ریبیف بعدة أسابیع إلى عدة سنواتٍ . قد یود طبیبك فحص ضغط دمك، ودمك (عدد الصفیحات)،<br />ووظائف كلیتك.<br />أبلغ طبیبك إذا كنت تعاني من مرض في<br />&bull; نخاع العظم،<br />&bull; الكلیة،<br />&bull; الكبد،<br />&bull; القلب،<br />&bull; الدرقیة،<br />&bull; أو إذا عانیت من الاكتئاب،<br />&bull; أو إذا كان لدیك أي تاریخ لنوبات صرعیة،<br />حتى یتمكن من مراقبة علاجك عن كثب ومراقبة أي تفاقم لھذه الحالات.<br />ریبیف والأدویة الأخرى<br />أخبر طبیبك أو الصیدلي إذا كنت تستعمل أيّ أدویة أخرى أو استعملتھا مؤخر ا أو قد تستعملھا. ینبغي تحدیدًا أن تبلغ طبیبك إذا كنت<br />تستخدم أدویة مضادة للصرع أو الاكتئاب.<br />الحمل والرضاعة<br />إذا كنتِ حاملا،ً أو تعتقدین أنكِ حامل أو تخططین لإنجاب طفل، فاطلبي نصیحة طبیبكِ أو الصیدلي قبل أخذ ھذا الدواء.<br />لا توجد آثار ضارة متوقعة على الطفل/الرضیع الذي یتلقى رضاعة طبیعیة. یمكن استعمال ریبیف خلال الرضاعة الطبیعیة.<br />القیادة واستعمال الآلات<br />قد تؤثر آثار المرض نفسھ أو علاجھ على قدرتك على القیادة أو استعمال الآلات. ینبغي أن تناقش ھذا مع طبیبك إذا كنت قلقاً.<br />یحتوي ریبیف على كحول بنزیلي<br />یحتوي ریبیف على 2.5 ملغ كحول بنزیلي في الجرعة. ممنوع إعطاؤه للأطفال المبتسرین أو الموالید الجدد. قد یسبب تفاعلات سامة<br />وتفاعلات تحسسیة للرضع والأطفال حتى عمر 3 سنواتٍ.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>ھذا الدواء للاستعمال متعدد الجرعات.<br />یتعین علیك استعمال ھذا الدواء دومًا بحسب توجیھات الطبیب تمامًا. ارجع لطبیبك إذا لم تكن متأكدًّا.<br />الجرعة<br />المرضى الذین عانوا من حدث سریري واحد<br />الجرعة المعتادة ھي 44 میكروغرامًا ( 12 ملیون وحدة دولیة) یتم إعطاؤھا ثلاث مراتٍ أسبوعیاً.<br />مرضى التصلب المتعدد<br />الجرعة المعتادة ھي 44 میكروغرامًا ( 12 ملیون وحدة دولیة) یتم إعطاؤھا ثلاث مراتٍ أسبوعیاً.<br />یوُصى بجرعة مخفضة 22 میكروغرامًا ( 6 ملیون وحدة دولیة) ثلاث مراتٍ أسبوعیاً للمرضى الذین لا یمكنھم تحمل الجرعة الأعلى.<br />ینبغي أخذ ریبیف ثلاث مراتٍ أسبوعیاً، وإذا أمكن:<br />&bull; في نفس الأیام الثلاث كل أسبوع (بفاصل 48 ساعة على الأقل؛ مثل الإثنین والأربعاء والجمعة)<br />&bull; في نفس الوقت من الیوم (یفضل في المساء).</p><p>الاستعمال للأطفال والمراھقین (من عمر عامین إلى 17 عامًا)<br />لم یتم عمل دراسات سریریة رسمیة على أطفال أو مراھقین. ومع ھذا تتوفر بعض البیانات السریریة التي تشیر إلى أن بیانات السلامة<br />الخاصة بالأطفال والمراھقین الذین یتلقون ریبیف 22 میكروغرامًا أو ریبیف 44 میكروغرامًا ثلاث مراتٍ أسبوعیاً مشابھة لتلك التي<br />تلُاحظ لدى البالغین.<br />الاستعمال للأطفال (تحت عمر عامین)<br />لا یوصى باستعمال ریبیف للأطفال تحت عمر عامین.<br />طریقة الحقن<br />&bull; ریبیف مخصص للحقن تحت الجلد.<br />&bull; یجب أن یتم أخذ الحقنة (الحقن) الأولى تحت إشراف متخصص رعایة صحیة مؤھل مناسب. بعد تلقي التدریب الكافي،<br />یمكنك أنت، أو قریب، أو صدیق، أو اختصاصي رعایة، استعمال خرطوشات ریبیف مع جھازك لأخذ الدواء في المنزل.<br />.Rebismart &bull; یجب استخدام الخرطوشة إما مع جھاز الحقن الإلكتروني<br />&bull; مرفق بجھازك تعلیمات الاستعمال كاملة.ً یرُجى اتباعھا بعنایة.<br />&bull; في ما یلي تعلیمات مختصرة لكیفیة استعمال خرطوشات ریبیف مع كل جھاز.<br />قبل أن تبدأ<br />&bull; اغسل یدیك جیدًا بالماء والصابون.<br />&bull; أخرِج خرطوشة ریبیف من العلبة المغلفة بأن تزیل الغطاء البلاستیك.<br />&bull; تحقق (بعد إخراجھا من الثلاجة مباشرةً) من أن الخرطوشة لم تتجمد عن طریق الخطأ في العبوة أو داخل الجھاز. ینبغي<br />عدم استعمال غیر المحلول الشفاف إلى الغائم الخالي من الجزیئات وعلامات التلف المرئیة.<br />&bull; لوضع الخرطوشة في الجھاز والقیام بالحقن، اتبع دلیل التعلیمات (تعلیمات الاستعمال) المرفق بجھازك.<br />موضع حقن ریبیف<br />&bull; اختر موضع حقن. سوف ینصحك طبیبك بخصوص مواضع الحقن الممكنة (تشمل<br />المواضع الجیدة أعلى الفخذین وأسفل البطن). ویوصى بأن تتعقب مواضع الحقن وتعید<br />تدویرھا، حتى لا یتم حقن منطقة واحدة بتكراریة عالیة لتقلل من خطر تنخر موضع<br />الحقن.<br />ملحوظة: لا تستخدم أي مناطق تشعر فیھا بكتل أو عقد صلبة أو ألم؛ وتحدث مع طبیبك<br />أو مختص الرعایة الصحیة بخصوص أي شيء تجده.<br />&bull; قبل الحقن، استخدم مسحة كحول لتنظیف الجلد في موضع الحقن. اترك الجلد یجف. إذا<br />بقي أثر من الكحول على الجلد، فقد تشعر بإحساس لاسع.<br />طریقة حقن ریبیف<br />&bull; سیخبرك طبیبك كیف تختار الجرعة الصحیحة 44 میكروغرامًا. یرُجى أیضًا قراءة التعلیمات في الدلیل المرفق بجھازك.<br />فیرُجى الانتقال إلى قسم ،Rebismart إذا كان قد وُصِف لك Rebismart &bull; من المحتمل أن طبیبك قد وصف لك جھاز<br />.Rebismart &quot;إذا كنت تستخدم</p><p>RebiSmart إذا كنت تستخدم</p><p>&bull; یرُجى التأكد من أن الجرعة التي تظھر على شاشة الجھاز تمثل الجرعة الموصوفة وھي<br />.(&deg; على الجلد بزاویة قائمة ( 90 RebiSmart 44 میكروغرامًا قبل الحقن. ضع<br />&bull; اضغط زر الحقن. خلال الحقن، سیوُمض الزر بضوء أخضر.<br />&bull; انتظر إلى أن ینطفئ الضوء الأخضر. یعُلمِك ھذا بأن الحقن قد اكتمل.<br />من موضع الحقن. RebiSmart &bull; انز</p><p>Rebismart بعد حقن ریبیف إما باستخدام</p><p>&bull; انزع الإبرة وتخلص منھا وفقاً لدلیل التعلیمات المرفق بجھازك.<br />&bull; دلكِّ برفق موضع الحقن بكرة قطن جافة أو شاش.<br />&bull; احفظ جھازك المحتوي على خرطوشة ریبیف حسب التعلیمات في القسم 5 &quot;طریقة حفظ ریبیف&quot;.</p><p>&nbsp;</p><p>إذا كانت لدیك أي أسئلة أخرى، فیرُجى طرحھا على طبیبك أو الممرضة أو الصیدلي.</p><p>إذا استعملت كمیة من ریبیف أكبر مما یجب<br />في حالة الجرعة الزائدة، اتصل بطبیبك فورًا.<br />إذا نسیت استعمال ریبیف<br />إذا فوتّ جرعة، فواصل الحقن من یوم الجرعة التالیة المقررة. لا تستعمل جرعة مزدوجة للتعویض عن جرعة قد نسیتھا.<br />إذا أوقفت استعمال ریبیف<br />قد لا یتم ملاحظة تأثیرات ریبیف فوریاً. لھذا ینبغي ألّا توقف استعمال ریبیف وإنما واصل استعمالھ بانتظام لتحقیق النتیجة المرجوة.<br />إذا لم تكن متأكدًا من المنافع، فیرُجى استشارة طبیبك.<br />ینبغي ألاّ توقف العلاج دون استشارة طبیبك أولا.ً<br />تحدث إلى طبیبك أو الصیدلي أو الممرضة إذا كانت لدیك أي أسئلة أخرى حول استعمال ھذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یسبب ھذا الدواء، شأنھ شأن جمیع الأدویة، آثار ا جانبیة، على الرغم من أنھا لا تصیب الجمیع.</p><p>&nbsp;</p><p>أبلغ طبیبك فورًا وأوقف استعمال ریبیف إذا أصابتك أي من الآثار الجانبیة الخطیرة التالیة:<br />&bull; تفاعلات تحسسیة (فرط تحسس) خطیرة. إذا شعرت بعد حقن ریبیف مباشرة بصعوبة تنفس مفاجئة، قد تظھر مصاحبة لتورم<br />في الوجھ أو الشفتین أو اللسان أو الحلق، وحمى قراصیة، وحكةّ في كامل الجسم، وإحساس بالضعف أو الإغماء، اتصل<br />بطبیبك فورًا أو اطلب الرعایة الطبیة العاجلة. ھذه التفاعلات نادرة (قد تصیب حتى واحد من كل 1000 شخص).<br />&bull; أبلغ طبیبك فورًا إذا أصابتك أي من الأعراض المحتملة التالیة لمشكلة في الكبد: یرقان (اصفرار الجلد أو الأجزاء البیضاء من<br />العین)، وحكةّ واسعة الانتشار، وفقدان شھیة مصحوب بغثیان وقيء، وسھولة تكدم الجلد. قد تصحب مشاكل الكبد الشدیدة<br />علامات إضافیة؛ مثل صعوبة التركیز، والنعاس، والارتباك.<br />&bull; الاكتئاب شائع (قد یصیب حتى واحد من كل 10 أشخاص) لدى مرضى التصلب المتعدد الذین یعالجَون. إذا شعرت أنك<br />مكتئب أو تأتیك أفكار انتحاریة، فأبلغ طبیبك فورًا.<br />استشر طبیبك إذا تعرضت لأي من الآثار الجانبیة التالیة:<br />&bull; الأعراض الشبیھة بالأنفلونزا، مثل الصداع، والحمى، وقشعریرة، وآلام العضلات والمفاصل؛ والتعب، والغثیان شائعة جدًا<br />(قد تصیب أكثر من واحد من كل 10 أشخاص).<br />عادة ما تكون ھذه الأعراض خفیفة، وھي أكثر شیوعاً عند بدء العلاج وتقل بالاستعمال المستمر.<br />للعمل على تقلیل ھذه الأعراض، قد ینصحك طبیبك بأخذ مسكّن ألم خافض للحمى قبل جرعة ریبیف ثم لمدة 24 ساعة بعد<br />كل حقن.<br />&bull; ردود الفعل في موضع الحقن بما في ذلك الاحمرار والتورم وتغیر اللون والالتھاب والألم وتھتك الجلد شائعة جدًا.<br />عادة ما یخف حدوث التفاعلات في موضع الحقن بمرور الوقت.<br />تلف الأنسجة (التنخر) وظھور خُرَّاج وكتلة في موضع الحقن أعراض غیر شائعة (قد تصیب حتى واحد من كل 100<br />شخص).<br />انظر التوصیات في قسم &quot;التحذیرات والاحتیاطات&quot; لتقلیل خطر التفاعلات في موضع الحقن.<br />قد تحدث عدوى في موضع الحقن (غیر شائعة)؛ قد یصبح الجلد متورمًا وموجعاً عند اللمس وصلباً وقد تصبح كامل المنطقة<br />مؤلمة جدًا. إذا أصابتك أي من ھذه الأعراض، فاتصل بطبیبك طلباً للنصیحة.<br />&bull; قد تحدث تغیرات في فحوص مختبریة معینة. تكون ھذه التغیرات غیر ملحوظة عمومًا بالنسبة للمریض (لا أعراض)، وعاد ة ما تكون عكوسة وخفیفة، ولا تتطلب علاجًا محددًا في معظم الأحیان.<br />قد ینخفض عدد خلایا الدم الحمراء أو خلایا الدم البیضاء أو الصفیحات إما بشكل منفرد (شائع جدًا) أو كلھا في وقت واحد<br />(نادر). یمكن أن تشمل الأعراض المحتملة الناتجة عن ھذه التغیرات التعب، أو ضعف القدرة على مكافحة العدوى، أو<br />التكدّم، أو النزیف غیر المبرر.<br />قد تختل اختبارات وظائف الكبد (شائع جدًا). تم أیضًا الإبلاغ عن التھاب الكبد (غیر شائع). إذا عانیت من أعراض تشیر إلى<br />اضطراب في الكبد، مثل فقدان الشھیة المصحوب بأعراض أخرى كالغثیان أو القيء أو الیرقان، فیرُجى الاتصال بطبیبك<br />فورًا (انظر أعلاه &quot;أبلغ طبیبك فورًا...&quot;).<br />&bull; الخلل الوظیفي في الغدة الدرقیة غیر شائع. قد تعمل الغدة الدرقیة إما بإفراط أو بقصور. لا یشعر المریض دائمًا تقریباً بھذه<br />التغیرات في نشاط الدرقیة كأعراض؛ ومع ھذا قد یوصي طبیبك باختبار حسب الاقتضاء.<br />&bull; الانتكاسة الزائفة للتصلب المتعدد (معدل التكرار غیر معروف): في بدایة علاجك بعقار ریبیف، توجد احتمالیة أن تعاني من<br />أعراض تشبھ تلك الخاصة بانتكاسة التصلب المتعدد. على سبیل المثال، قد تشعر أن عضلاتك متوترة جدًا أو ضعیفة جدًا،<br />لدرجة تمنعك من التحرك كما تشاء. تكون ھذه الأعراض مصحوبة في بعض الحالات بالحمى أو الأعراض الشبیھة<br />بالأنفلونزا المذكورة أعلاه. إذا لاحظت أي من ھذه الآثار الجانبیة، فتحدث مع طبیبك.<br />تشمل الآثار الجانبیة المحتملة الأخرى:<br />شائعة جدًا (قد تصیب أكثر من واحد من كل 10 أشخاص):<br />&bull; الصداع<br />شائعة (قد تصیب حتى واحد من كل 10 أشخاص):<br />&bull; الأرق (صعوبة النوم)<br />&bull; الإسھال، الغثیان، القيء<br />&bull; الحكةّ، الطفح (طفوح الجلد)<br />&bull; ألم العضلات والمفاصل<br />&bull; التعب، الحمى، القشعریرة</p><p>&bull;تساقط الشعر</p><p>غیر شائعة (قد تصیب حتى واحد من كل 100 شخص):<br />&bull; الشرى<br />&bull; النوبات الصرعیة<br />&bull; التھاب الكبد<br />&bull; صعوبات التنفس<br />&bull; التجلطات الدمویة مثل الخثار الوریدي العمیق<br />&bull; اضطرابات الشبكیة (مؤخرة العین) مثل التھاب أو جلطات دمویة ینشأ عنھا اضطرابات في الإبصار (اضطرابات الإبصار،<br />فقدان البصر)<br />&bull; زیادة التعرّق<br />نادرة (قد تصیب حتى واحد من كل 1000 شخص):<br />&bull; محاولة الانتحار<br />&bull; التفاعلات الجلدیة الخطیرة - بعضھا مع آفات مخاطیة<br />&bull; الجلطات الدمویة في الأوعیة الدمویة الصغیرة التي یمكنھا التأثیر على كلیتیك (الفرُفرُِیة القلیلة الصفیحات الخثاریة أو<br />المتلازمة الیوریمیة الانحلالیة). قد تشمل الأعراض زیادة التكدّم، أو النزیف، أو الحمى، أو الضعف الشدید، أو الصداع، أو<br />الدوّار، أو الدوخة. قد یجد طبیبك تغیرات في دمك وفي وظائف كلیتیك.<br />&bull; الذئبة الحمامیة الناجمة عن الأدویة: أثر جانبي نتیجة استخدام ریبیف على المدى الطویل. قد تشمل الأعراض ألم العضلات،<br />وألم المفاصل، والتورم، والطفح. قد تعاني أیضًا من علامات أخرى مثل الحمى، وخسارة الوزن، والتعب. عادة ما تختفي<br />الأعراض خلال أسبوع أو أسبوعین بعد وقف العلاج.<br />&bull; مشاكل الكلى بما في ذلك التندب الذي قد یقلل وظائف كلیتك. إذا أصُِبت ببعض أو كل ھذه الأعراض:<br />- البول الرغوي<br />- التعب<br />- التورم، تحدیدًا في الكاحلین والجفون، وزیادة الوزن. أبلغ طبیبك لأنھا قد تكون علامات لمشكلة محتملة في الكلیة.<br />تم الإبلاغ عن الآثار الجانبیة التالیة مع إنترفیرون بیتا (معدل التكرار غیر معروف)<br />&bull; الدُوار<br />&bull; العصبیة<br />&bull; فقدان الشھیة<br />&bull; توسع الأوعیة الدمویة والخفقان<br />&bull; عدم انتظام و/أو تغیرات في تدفق الدورة الشھریة<br />&bull; ارتفاع ضغط الدم الشریاني الرئوي - مرض تضیقُّ شدید للأوعیة الدمویة في الرئتین ینتج عنھ ضغط دم مرتفع في الأوعیة<br />الدمویة التي تحمل الدم من القلب إلى الرئتین. لوُحظ ارتفاع ضغط الدم الشریاني الرئوي في نقاط زمنیة مختلفة خلال العلاج،<br />بما في ذلك بعد عدة سنوات من بدء العلاج بعقار ریبیف.<br />یجب ألاّ توقف العلاج أو تعدّلھ بدون استشارة طبیبك</p><p>الأطفال والمراھقین<br />الآثار الجانبیة لدى الأطفال والمراھقین مشابھة لتلك التي لوُحظت لدى البالغین</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ ھذا الدواء بعیدًا عن متناول الأطفال ورؤیتھم.<br />انتھاء الصلاحیة). ) EXP لا تستخدم ھذا الدواء بعد تاریخ انتھاء صلاحیتھ المدوّن على الملصق بجوار الاختصار<br />یحُفظ في الثلاجة (ما بین 2 إلى 8 درجاتٍ مئویة).<br />ویحُظر تجمیده. (لمنع التجمد غیر المقصود، تجنب وضعھ بالقرب من حجیرة المجمّد).</p><p>یسُتخدم خلال 28 یومًا بعد أول حقن.<br />المحتوي على خرطوشة ریبیف مسبقة التعبئة داخل علبة حفظ الجھاز في مبرِّد (ما بین 2 إلى 8 ( RebiSmart) یجب حفظ الجھاز<br />درجاتٍ مئویة). لغرض الاستخدام المتنقل، یمكنك إخراج ریبیف من المبرّد وحفظھ في درجة حرارة لا تزید عن 25 درجة مئویة<br />لفترة زمنیة واحدة أقصاھا 14 یومًا. یجب بعدھا إعادة ریبیف إلى المبرد واستخدامھ قبل تاریخ انتھاء الصلاحیة.<br />احفظ الدواء في العبوة الأصلیة لحمایتھ من الضوء.<br />لا تستعمل ھذا الدواء إذا لاحظت أيّ مؤشرات تدلّ على تلفھ، كأن لا یعود المحلول شفافاً أو إذا احتوى على جزیئات.<br />لا ترمِ أيّ أدویة في میاه الصرف أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد تستخدمھا. تساعد ھذه<br />التدابیر على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتویات العبوة ومعلومات أخرى ما یحتوي علیھ ریبیف<br />(IU) &bull; المادة الفعّالة ھي إنترفیرون بیتا- 1أ. تحتوي كل خرطوشة على 132 میكروغرامًا یعادل 36 ملیون وحدة دولیة<br />إنترفیرون بیتا- 1أ.<br />&bull; المكونات الأخرى ھي مانیتول، بولوكسامیر 188 ، ل-مثیونین، كحول بنزیلي، أسیتات صودیوم، حمض أسیتیك، ھیدروكسید<br />صودیوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل ریبیف ومحتویات العبوة<br />خرطوشة مسبقة التعبئة (زجاج من النوع 1) مع كباس بمصد (مطاط) وغطاء مجعد (ألومنیوم ومطاط ھالوبیتیل)، تحتوي على 1.5<br />مل محلول للحقن. حجم العبوة 4 أو 12 خرطوشة. قد لا تسُوَّق جمیع أحجام العلب.<br />Rebismart یجب استخدام الخرطوشة مع جھاز الحقن الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل رخصة التسویق<br />میرك سیرونو اوروبا لیمتد<br />مارش وال 56<br />لندن, المملكھ المتحده</p><p>جھة التصنیع</p><p>Merck Serono S.p.A.<br />Via delle Magnolie 15<br />I-70026 Modugno (Bari)<br />Italy</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            جرت آخر مراجعة لھذه النشرة في 17 اكتوبر 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rebif 44 micrograms/0.5 mL solution for injection in cartridge
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled cartridge contains 132 micrograms (36 MIU*) of interferon beta-1a** in 1.5 mL solution, corresponding to 88 micrograms/ml.
* Million International Units measured by cytopathic effect (CPE) bioassay against the in-house interferon beta-1a standard which is calibrated against the current international NIH standard (GB-23-902-531).
** produced in Chinese hamster ovary Cells (CHO-K1) by recombinant DNA technology.
Excipient with known effect: 7.5 mg benzyl alcohol
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in cartridge.
Clear to opalescent solution, with pH 3.7 to 4.1 and osmolarity 250 to 450 mOsm/L.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rebif is indicated for the treatment of<br />&bull; patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1)<br />&bull; patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section 5.1).<br />Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.<br />For patients initiating treatment with Rebif, Rebif 8.8 micrograms and Rebif 22 micrograms are available in a pack that corresponds to the patient needs for the first month of therapy.<br />Posology<br />When first starting treatment with Rebif, in order to allow tachyphylaxis to develop thus reducing adverse reactions it is recommended that patients be started at 8.8 micrograms dose subcutaneously and the dose be increased over a 4-week period to the targeted dose, according to the following schedule</p><p>Recommended Titration<br />(% of final dose)<br />Titration dose for Rebif 44 micrograms three times per week (tiw)<br />Weeks 1-2<br />20%<br />8.8 micrograms tiw<br />Weeks 3&ndash;4<br />50%<br />22 micrograms tiw<br />Weeks 5+<br />100%<br />44 micrograms tiw</p><p>First demyelinating event<br />The posology for patients who have experienced a first demyelinating event is 44 micrograms of Rebif given three times per week by subcutaneous injection.<br />Relapsing multiple sclerosis<br />The recommended posology of Rebif is 44 micrograms given three times per week by subcutaneous injection. A lower dose of 22 micrograms, also given three times per week by subcutaneous injection, is recommended for patients who cannot tolerate the higher dose in view of the treating specialist.<br />Paediatric population<br />No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. However, a paediatric retrospective cohort study collected safety data with Rebif from medical records in children (n=52) and adolescents (n=255). The results of this study suggest that the safety profile in children (2 to 11 years old) and in adolescents (12 to 17 years old) receiving Rebif 22 micrograms or 44 micrograms subcutaneous three times per week is similar to that seen in adults.<br />The safety and efficacy of Rebif in children below 2 years of age have not yet been established. Rebif should not be used in this age group.<br />Method of administration<br />Rebif solution for subcutaneous injection in a cartridge is intended for multidose use with either the Rebismart electronic injection device following adequate training of the patient and/or carer. The physician should discuss with the patient which device is the most appropriate.<br />For administration, the instructions provided in the package leaflet and in the instruction manual (Instructions for Use) provided with Rebismart.<br />Prior to injection and for an additional 24 hours after each injection, an antipyretic analgesic is advised to decrease flu-like symptoms associated with Rebif administration.<br />At the present time, it is not known for how long patients should be treated. Safety and efficacy with Rebif have not been demonstrated beyond 4 years of treatment. It is recommended that patients should be evaluated at least every second year in the 4-year period after initiation of treatment with Rebif and a decision for longer term treatment should then be made on an individual basis by the treating physician.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to natural or recombinant interferon beta or to any of the excipients listed in section 6.1.
• Current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability<br />In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.<br />General recommendations<br />Patients should be informed of the most frequent adverse reactions associated with interferon beta administration, including symptoms of the flu-like syndrome (see section 4.8). These symptoms tend to be most prominent at the initiation of therapy and decrease in frequency and severity with continued treatment.<br />Thrombotic microangiopathy (TMA)<br />Cases of thrombotic microangiopathy, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS), including fatal cases, have been reported with interferon beta products. Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with interferon beta. Early clinical features include thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion, paresis) and impaired renal function. Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte fragmentation) on a blood film. Therefore, if clinical features of TMA are observed, further testing of blood platelet levels, serum LDH, blood films and renal function is recommended. If TMA is diagnosed, prompt treatment is required (considering plasma exchange) and immediate discontinuation of Rebif is recommended.<br />Depression and suicidal ideation<br />Rebif should be administered with caution to patients with previous or current depressive disorders in particular to those with antecedents of suicidal ideation (see section 4.3). Depression and suicidal ideation are known to occur in increased frequency in the multiple sclerosis population and in association with interferon use. Patients treated with Rebif should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician. Patients exhibiting depression should be monitored closely during therapy with Rebif and treated appropriately. Cessation of therapy with Rebif should be considered (see sections 4.3 and 4.8).<br />Seizure disorders<br />Rebif should be administered with caution to patients with a history of seizures, to those receiving treatment with anti-epileptics, particularly if their epilepsy is not adequately controlled with antiepileptics (see sections 4.5 and 4.8).<br />Cardiac disease<br />Patients with cardiac disease, such as angina, congestive heart failure or arrhythmia, should be closely monitored for worsening of their clinical condition during initiation of therapy with interferon beta-1a. Symptoms of the flu-like syndrome associated with interferon beta-1a therapy may prove stressful to patients with cardiac conditions.</p><p>Injection site necrosis<br />Injection site necrosis (ISN) has been reported in patients using Rebif (see section 4.8). To minimise the risk of injection site necrosis patients should be advised to:<br />&bull; use an aseptic injection technique,<br />&bull; rotate the injection sites with each dose.<br />The procedure for the self-administration by the patient should be reviewed periodically especially if injection site reactions have occurred.<br />If the patient experiences any break in the skin, which may be associated with swelling or drainage of fluid from the injection site, the patient should be advised to consult with their physician before continuing injections with Rebif. If the patient has multiple lesions, Rebif should be discontinued until healing has occurred. Patients with single lesions may continue provided that the necrosis is not too extensive.<br />Hepatic dysfunction<br />In clinical trials with Rebif, asymptomatic elevations of hepatic transaminases (particularly alanine aminotransferase (ALT)) were common and 1-3% of patients developed elevations of hepatic transaminases above 5 times the upper limit of normal (ULN). In the absence of clinical symptoms, serum ALT levels should be monitored prior to the start of therapy, at months 1, 3 and 6 on therapy and periodically thereafter. Dose reduction of Rebif should be considered if ALT rises above 5 times the ULN, and gradually re-escalated when enzyme levels have normalized. Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT (&gt;2.5 times ULN). Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear.<br />Rebif, like other interferons beta, has a potential for causing severe liver injury including acute hepatic failure (see section 4.8). The majority of the cases of severe liver injury occurred within the first six months of treatment. The mechanism for the rare symptomatic hepatic dysfunction is not known. No specific risk factors have been identified.<br />Renal and urinary disorders<br />Nephrotic syndrome<br />Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon-beta products. Events were reported at various time points during treatment and may occur after several years of treatment with interferon-beta. Periodic monitoring of early signs or symptoms, e.g. oedema, proteinuria and impaired renal function is recommended, especially in patients at higher risk of renal disease. Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with Rebif should be considered.<br />Laboratory abnormalities<br />Laboratory abnormalities are associated with the use of interferons. The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms. Therefore, in addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, liver enzyme monitoring and complete and differential blood cell counts and platelet counts are recommended at regular intervals (1, 3 and 6 months) following introduction of Rebif therapy and then periodically thereafter in the absence of clinical symptoms. These should be more frequent when initiating Rebif 44 micrograms.</p><p>Thyroid disorders<br />Patients being treated with Rebif may occasionally develop new or worsening thyroid abnormalities. Thyroid function testing is recommended at baseline and if abnormal, every 6-12 months following initiation of therapy. If tests are normal at baseline, routine testing is not needed but should be performed if clinical findings of thyroid dysfunction appear (see section 4.8).<br />Severe renal or hepatic failure and severe myelosuppression<br />Caution should be used, and close monitoring considered when administering interferon beta-1a to patients with severe renal and hepatic failure and to patients with severe myelosuppression.<br />Neutralising antibodies<br />Serum neutralising antibodies against interferon beta-1a may develop. The precise incidence of antibodies is as yet uncertain. Clinical data suggest that after 24 to 48 months of treatment with Rebif 44 micrograms, approximately 13 to 14% of patients develop persistent serum antibodies to interferon beta-1a. The presence of antibodies has been shown to attenuate the pharmacodynamic response to interferon beta-1a (beta-2 macroglobulin and neopterin). Although the clinical significance of the induction of antibodies has not been fully elucidated, the development of neutralising antibodies is associated with reduced efficacy on clinical and MRI variables. If a patient responds poorly to therapy with Rebif, and has neutralising antibodies, the treating physician should reassess the benefit/risk ratio of continued Rebif therapy.<br />The use of various assays to detect serum antibodies and differing definitions of antibody positivity limits the ability to compare antigenicity among different products.<br />Other forms of multiple sclerosis<br />Only sparse safety and efficacy data are available from non-ambulatory patients with multiple sclerosis. Rebif has not yet been investigated in patients with primary progressive multiple sclerosis and should not be used in these patients.<br />Benzyl alcohol<br />This medicinal product contains 2.5 mg benzyl alcohol per dose of 0.5 ml.<br />It must not be given to premature babies or neonates. It may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with interferon beta-1a in humans.<br />Interferons have been reported to reduce the activity of hepatic cytochrome P450-dependent enzymes in humans and animals. Caution should be exercised when administering Rebif in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. antiepileptics and some classes of antidepressants.<br />The interaction of Rebif with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically. Clinical studies indicate that multiple sclerosis patients can receive Rebif and corticosteroids or ACTH during relapses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />A large amount of data (more than 1,000 pregnancy outcomes) from registries and post-marketing experience indicates no increased risk of major congenital anomalies after pre-conception exposure to interferon beta or such exposure during the first trimester of pregnancy. However, the duration of exposure during the first trimester is uncertain, because data were collected when interferon beta use was contraindicated during pregnancy, and treatment likely interrupted when the pregnancy was detected and/or confirmed. Experience with exposure during the second and third trimester is very limited.<br />Based on animal data (see section 5.3), there is a possibly increased risk for spontaneous abortion. The risk of spontaneous abortions in pregnant women exposed to interferon beta cannot adequately be evaluated based on the currently available data, but the data do not suggest an increased risk so far.<br />If clinically needed, the use of Rebif may be considered during pregnancy<br />Breast-feeding<br />Limited information available on the transfer of interferon beta-1a into breast milk, together with the chemical/physiological characteristics of interferon beta, suggests that levels of interferon beta-1a excreted in human milk are negligible. No harmful effects on the breastfed new born/infant are anticipated.<br />Rebif can be used during breast-feeding.<br />Fertility<br />The effects of Rebif on fertility have not been investigated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Central nervous system-related adverse events associated with the use of interferon beta (e.g. dizziness) might influence the patient&#39;s ability to drive or use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The highest incidence of adverse reactions associated with Rebif therapy is related to flu-like syndrome. Flu-like symptoms tend to be most prominent at the initiation of therapy and decrease in frequency with continued treatment. Approximately 70 % of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment. Approximately 30 % of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. Asymptomatic increases in laboratory parameters of hepatic function and decreases in white blood cells are also common.<br />The majority of adverse reactions observed with interferon beta-1a are usually mild and reversible and respond well to dose reductions. In case of severe or persistent undesirable effects, the dose of Rebif may be temporarily lowered or interrupted, at the discretion of the physician.</p><p>List of adverse reactions<br />The adverse reactions presented have been identified from clinical studies as well as from post-marketing reports (an asterisk [*] indicates adverse reactions identified during post-marketing surveillance). The following definitions apply to the frequency terminology used hereafter: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), frequency not known (cannot be estimated from the available data).<br />Blood and the lymphatic system disorders<br />Very common: Neutropenia, lymphopenia, leukopenia, thrombocytopenia, anaemia<br />Rare: Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uremic syndrome* (class label for interferon beta products, see section 4.4), pancytopenia*<br />Endocrine disorders<br />Uncommon: Thyroid dysfunction, most often presenting as hypothyroidism or hyperthyroidism<br />Immune system disorders<br />Rare: Anaphylactic reactions*<br />Hepatobiliary disorders<br />Very common: Asymptomatic transaminase increase<br />Common: Severe elevations in transaminases<br />Uncommon: Hepatitis with or without icterus*<br />Rare: Hepatic failure* (see section 4.4), autoimmune hepatitis*<br />Psychiatric disorders<br />Common: Depression, insomnia<br />Rare: Suicide attempt*<br />Nervous system disorders<br />Very common: Headache<br />Uncommon: Seizures*<br />Frequency not known: Transient neurological symptoms (i.e. hypoesthesia, muscle spasm, paraesthesia, difficulty in walking, musculoskeletal stiffness) that may mimic multiple sclerosis exacerbations*<br />Eye disorders<br />Uncommon: Retinal vascular disorders (i.e. retinopathy, cotton wool spots, obstruction of retinal artery or vein) *<br />Vascular disorders<br />Uncommon: Thromboembolic events*<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon: Dyspnoea*<br />Not known: Pulmonary arterial hypertension* (class label for interferon products, see below Pulmonary arterial hypertension)<br />Gastrointestinal disorders<br />Common: Diarrhoea, vomiting, nausea<br />Skin and subcutaneous tissue disorders<br />Common: Pruritus, rash, erythematous rash, maculo-papular rash, alopecia*<br />Uncommon: Urticaria*</p><p>Rare: Quincke&rsquo;s oedema (angio-oedema) *, erythema multiforme*, erythema multiforme-like skin reactions*, Stevens Johnson syndrome*<br />Musculoskeletal and connective disorders<br />Common: Myalgia, arthralgia<br />Rare: Drug-induced lupus erythematosus*<br />Renal and urinary disorders<br />Rare: Nephrotic syndrome*, glomerulosclerosis* (see section 4.4)<br />General disorders and administration site conditions<br />Very common: Injection site inflammation, injection site reaction, influenza-like symptoms<br />Common: Injection site pain, fatigue, rigors, fever<br />Uncommon: Injection site necrosis, injection site mass, injection site abscess, injection site infections*, increased sweating*<br />Rare: Injection site cellulitis*<br />Paediatric population<br />No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. Limited safety data suggest that the safety profile in children and adolescents (2 to 17 years old) receiving Rebif 22 micrograms or 44 micrograms three times weekly is similar to that seen in adults.<br />Class effects<br />The administration of interferons has been associated with anorexia, dizziness, anxiety, arrhythmias, vasodilation and palpitation, menorrhagia and metrorrhagia.<br />An increased formation of auto-antibodies may occur during treatment with interferon beta.<br />Pulmonary arterial hypertension<br />Cases of pulmonary arterial hypertension (PAH) have been reported with interferon beta products. Events were reported at various time points including up to several years after starting treatment with interferon beta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of overdose, patients should be hospitalised for observation and appropriate supportive treatment should be given.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunostimulants, Interferons, ATC code: L03AB07<br />Interferons are a group of endogenous glycoproteins endowed with immunomodulatory, antiviral and antiproliferative properties.<br />Rebif (interferon beta-1a) shares the same amino acid sequence with endogenous human interferon beta. It is produced in mammalian cells (Chinese hamster ovary) and is therefore glycosylated like the natural protein.<br />Regardless of the route of dosing, pronounced pharmacodynamic changes are associated with the administration of Rebif. After a single dose, intracellular and serum activity of 2&rsquo;5&rsquo;OAS synthetase and serum concentrations of beta-2 microglobulin and neopterin increase within 24 hours and start to decline within 2 days. Intramuscular and subcutaneous administrations produce fully superimposable responses. After repeated subcutaneous administration every 48 hours for 4 doses, these biological responses remain elevated, with no signs of tolerance development.<br />Biological response markers (e.g., 2&rsquo;,5&rsquo;-OAS activity, neopterin and beta 2-microglobulin) are induced by interferon beta-1a following subcutaneous doses administered to healthy volunteer subjects. Time to peak concentrations following a single subcutaneous injection were 24 to 48 hours for neopterin, beta-2-microglobulin and 2&rsquo;5&rsquo;OAS, 12 hours for MX1 and 24 hours for OAS1 and OAS2 gene expression. Peaks of similar height and time were observed for most of these markers after first and sixth administration.<br />The precise mechanism of action of Rebif in multiple sclerosis is still under investigation.<br />Single clinical event suggestive of multiple sclerosis<br />One 2-year controlled clinical trial with Rebif was performed in patients with a single clinical event suggestive of demyelination due to multiple sclerosis. The patients enrolled into the trial had at least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 mm, at least one ofwhich is ovoid or periventricular or infratentorial. Any disease other than multiple sclerosis that could better explain signs and symptoms of the patient had to be excluded.<br />Patients were randomised in a double-blind manner to either Rebif 44 micrograms given three times per week, Rebif 44 micrograms once weekly, or placebo. If a second clinical demyelinating event occurred confirming definite multiple sclerosis, patients switched to the recommended posology of Rebif 44 micrograms three times per week in an open label manner, while maintaining blinding as to initial randomisation.<br />Efficacy results of Rebif 44 micrograms given three times per week compared to placebo from this study are as follows:<br />Parameter<br />Statistics<br />Treatment<br />Treatment Comparison<br />Rebif 44 mcg tiw versus Placebo<br />Placebo (n=171)<br />Rebif 44<br />mcg tiw* (n=171)<br />Risk Reduction<br />Cox&rsquo;s Proportional Hazard Ratio [95% CI]<br />Log-Rank<br />p-value<br />McDonald (2005) Conversion<br />Number of events<br />144<br />106<br />51%<br />0.49 [0.38;0.64]<br />&lt;0.001<br />KM Estimate<br />85.8%<br />62.5%<br />CDMS Conversion<br />Number of events<br />60<br />33<br />52%<br />0.48 [0.31;0.73]<br />&lt;0.001<br />KM Estimate<br />37.5%<br />20.6%<br />Mean CUA Lesions per Subject per Scan During the Double Blind Period<br />Least Square Means (SE)<br />2.58 (0.30)<br />0.50 (0.06)<br />81%<br />0.19 [0.14;0.26]<br />&lt;0.001<br />* tiw &ndash; three times per week<br />For the time being there is no well-established definition of a high-risk patient, although a more conservative approach is to accept at least nine T2 hyperintense lesions on the initial scan and at least one new T2 or one new Gd-enhancing lesion on a follow-up scan taken at least 1 month after the initial scan. In any case, treatment should only be considered for patients classified as high risk.<br />Relapsing-remitting multiple sclerosis<br />The safety and efficacy of Rebif has been evaluated in patients with relapsing-remitting multiple sclerosis at doses ranging from 11 to 44 micrograms (3-12 million IU), administered subcutaneously three times per week. At licensed posology, Rebif 44 micrograms has been demonstrated to decrease the incidence (approximately 30% over 2 years) and severity of clinical relapses in patients with at least 2 exacerbations in the previous 2 years and with an EDSS of 0-5.0 at entry. The proportion of patients with disability progression, as defined by at least one-point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 27% (Rebif 44 micrograms). Over 4 years, the reduction in the mean exacerbation rate was 22% in patients treated with Rebif 22 micrograms, and 29% in patients treated with Rebif 44 micrograms group compared with a group of patients treated with placebo for 2 years and then either Rebif 22 or Rebif 44 micrograms for 2 years.<br />Secondary progressive multiple sclerosis<br />In a 3-year study in patients with secondary progressive multiple sclerosis (EDSS 3-6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8 weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately 30%. If the patient population was divided into 2 subgroups (those with and those without relapses in the 2-year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif 22 micrograms and44 micrograms combined). These results obtained in a subgroup of patient&#39;s posteriori should be interpreted cautiously.<br />Primary progressive multiple sclerosis<br />Rebif has not yet been investigated in patients with primary progressive multiple sclerosis and should not be used in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />In healthy volunteers after intravenous administration, interferon beta-1a exhibits a sharp multi-exponential decline, with serum levels proportional to the dose. Subcutaneous and intramuscular administrations of Rebif produce equivalent exposure to interferon beta.<br />Distribution<br />Following repeated subcutaneous injections of 22 and 44 micrograms doses of Rebif maximum concentrations were typically observed after 8 hours, but this was highly variable.<br />Elimination<br />After repeated subcutaneous doses in healthy volunteers, the main PK parameters (AUCtau and Cmax) increased proportional to the increased in dose from 22 micrograms to 44 micrograms. The estimated apparent half-life is 50 to 60 hours, which is in line with the accumulation observed after multiple dosing.<br />Metabolism<br />Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, and genotoxicity.<br />Rebif has not been investigated for carcinogenicity.<br />A study on embryo/foetal toxicity in monkeys showed no evidence of reproductive disturbances. An increased risk of abortions has been reported in animal studies of other alpha and beta interferons. No information is available on the effects of the interferon beta-1a on male fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol 67.5 mg<br />(Poloxamer 188) 0.75 mg<br />L-methionine 0.18 mg<br />Benzyl alcohol 7.5 mg<br />Sodium acetate 1.5 ml<br />Acetic acid for pH adjustment<br />Sodium hydroxide for pH adjustment<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months.
After first injection use within 28 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C) away from the cooling element. Do not freeze. Store the cartridge in the original package in order to protect from light.<br />The device (Rebismart) containing a pre-filled cartridge of Rebif must be stored in the device storage box in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />For the purpose of ambulatory use, the patient may remove Rebif from the refrigerator and store it not above 25&deg;C for one single period of up to 14 days. Rebif must then be returned to the refrigerator and used before the expiry date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartridges (type 1 glass) with a plunger stopper (rubber) and crimp cap (aluminium and halo butyl rubber) containing 1.5 mL solution for injection.<br />Pack size of 4 cartridges.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution for injection in a pre-filled cartridge is ready for use with the Rebismart electronic injection device, see section 6.4. Not all injection devices may be available.<br />For multidose use. Only clear to opalescent solution without particles and without visible signs of deterioration should be used.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Merck Serono Europe Ltd
56 Marsh Wall
London E14 9TP
United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 / October / 2019.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>